Merit Financial Group
PACB icon

Merit Financial Group’s Pacific Biosciences PACB Stock Holding History

Merit Financial Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-11,005
Closed -$18.5K – 2533
2026
Q2 		$18.5K Sell
11,005
-4,562
-29% -$6.63K ﹤0.01% 2332
2026
Q1 		$20.5K Buy
+15,567
New +$27.8K ﹤0.01% 2097

Other funds holding PACB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bourne Lent Asset Management
Bourne Lent Asset Management Pawling, New York $293M AUM 24.01% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Merit Financial Group's PACB Position: Q3 2026 in Review

Merit Financial Group sold out of Pacific Biosciences (PACB) in Q3 2026, closing a stake of 11,005 shares — an estimated $18.5K sold.

Merit Financial Group first reported a position in PACB in Q1 2026 and held it in 2 quarters. The position peaked at $20.5K in Q1 2026. 107 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Merit Financial Group reported no remaining Pacific Biosciences position as of Q3 2026 after selling out during the quarter.
  • Merit Financial Group sold 11,005 Pacific Biosciences shares in Q3 2026, an estimated $18.5K.
  • Merit Financial Group first reported a position in Pacific Biosciences in Q1 2026 and held it in 2 quarters.
  • Merit Financial Group's Pacific Biosciences position peaked at $20.5K in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.